New one-time gene therapies for Sickle Cell Disease, approved in December, have introduced a significant breakthrough for over 100,000 African Americans suffering from the condition. However, the excitement is tempered by the challenge of affording these treatments, which come with a seven-figure price tag. Discussions are underway between biotech firms, such as Vertex Pharmaceuticals ($VRTX) and Bluebird Bio ($BLUE), and federal health officials to address this health equity issue. The high cost of these therapies poses a challenge to providing equitable access, sparking a conversation on potential new payment models to manage these expenses.
For those suffering from rare diseases, treatment options can be painfully limited. But cutting edge gene therapies are finally bringing hope to thousands of sufferers. https://t.co/RRMKXDgglI @AngieAsimus #7NEWS https://t.co/DboVmgAbPa
Rare disease R&D requires a patients-first approach. This community is often met with few treatment options and a challenging diagnosis journey. Yesterday, we shared how @Amgen is advancing our clinical programs and leveraging our capabilities to champion those with unmet needs.…
Over 100,000 African Americans suffer from Sickle Cell Disease. Coming up on @NBCNewsNow with @simplyzinhle: How new breakthrough treatments are offering hope, but their high price tags are posing a challenge to providing equitable access. https://t.co/rQTtt6zGgk
New Sickle Cell gene therapies are a breakthrough, but solving how to pay the 7-figure treatments is a struggle. It's a question of health equity, but discussions happening now with $BLUE and $VRTX also serve as an opportunity for new payment models. https://t.co/rQTtt6zGgk
There was great optimism when new one-time gene therapies for Sickle Cell were approved in December. Now comes the hard part: paying for the 7-figure treatments. Coming up on @moneymoverscnbc how $VRTX $BLUE and federal health officials are working on this health equity problem.
New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle https://t.co/z7MEajYPHt